Polaris AI Pharma Corp
041910
Company Profile
Business description
Polaris AI Pharma Corp is engaged in the production of raw pharmaceutical ingredients. It focuses on generic drugs and produces about 40 types of raw medicines, including asthma treatments, gastric ulcer treatments, and alcohol dependence treatments, and supplies them domestically and internationally.
Contact
25 Balangongdan-ro, Hyangnam-eup
Gyeonggi-do
Hwaseong-si
KORT: +82 318314800
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
162
Stocks News & Analysis
stocks
Going into earnings, is Netflix stock a buy, a sell, or fairly valued?
Watching sales growth and the potential for margin expansion, here’s what we think of Netflix stock.
stocks
Bapcor is paying for the sins of its past
Shares plunged over 17% after reporting disappointing results.
stocks
Overvalued ASX share as market underestimates downside risks
Growth outlook solid, but upside more than priced in.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,391.20 | 17.50 | 0.19% |
| CAC 40 | 8,206.07 | 31.87 | 0.39% |
| DAX 40 | 24,258.80 | 427.81 | 1.80% |
| Dow JONES (US) | 46,706.58 | 515.97 | 1.12% |
| FTSE 100 | 9,403.57 | 49.00 | 0.52% |
| HKSE | 26,347.37 | 488.54 | 1.89% |
| NASDAQ | 22,990.54 | 310.57 | 1.37% |
| Nikkei 225 | 49,929.81 | 744.31 | 1.51% |
| NZX 50 Index | 13,356.12 | 11.16 | 0.08% |
| S&P 500 | 6,735.13 | 71.12 | 1.07% |
| S&P/ASX 200 | 9,094.10 | 18.20 | 0.20% |
| SSE Composite Index | 3,899.64 | 35.75 | 0.93% |